Research programme: nanoparticle-based ovarian cancer therapeutics - Cascade Prodrug/Oregon State University
Latest Information Update: 01 Aug 2016
At a glance
- Originator Cascade Prodrug; Oregon State University
- Class Antineoplastics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Ovarian cancer